| Literature DB >> 26497880 |
Seung Rye Kim1, So Yeon Jeon1, Seung-Min Lee2,3.
Abstract
BACKGROUND: The quality of dietary fats is associated with risk of cardiovascular diseases (CVD). We aimed to investigate the association between fatty acids in erythrocyte membrane phospholipids and CVD risk factors in middle-aged Korean adults.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26497880 PMCID: PMC4619393 DOI: 10.1186/s12944-015-0135-x
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
General characteristics of study subjects
| Total | Male | Female | Male–female | |
|---|---|---|---|---|
| ( | ( | ( |
| |
| Age, years | 52.56 ± 4.751 | 53.43 ± 4.231 | 51.18 ± 5.288 | 0.082 |
| BMI, kg/m2 | 23.55 ± 2.624 | 24.47 ± 2.295 | 22.10 ± 2.496 | 0.001 |
| SBP, mmHg | 116.4 ± 16.93 | 120.0 ± 16.84 | 110.8 ± 15.87 | 0.046 |
| DBP, mmHg | 69.91 ± 11.68 | 72.17 ± 11.95 | 66.32 ± 10.50 | 0.065 |
| TG, mg/dL | 117.5 ± 61.40 | 131.0 ± 54.67 | 96.00 ± 66.51 | 0.035 |
| TC, mg/dL | 200.8 ± 33.97 | 195.3 ± 33.97 | 209.4 ± 32.90 | 0.129 |
| HDL-C, mg/dL | 53.51 ± 10.96 | 49.94 ± 8.691 | 59.18 ± 11.95 | 0.001 |
| LDL-C, mg/dL | 123.7 ± 30.55 | 119.3 ± 31.14 | 130.7 ± 28.90 | 0.171 |
| AI | 2.848 ± 0.768 | 2.966 ± 0.680 | 2.611 ± 0.857 | 0.142 |
| Apo B, g/L | 0.985 ± 0.186 | 0.998 ± 0.178 | 0.964 ± 0.201 | 0.512 |
| FBS, mg/dl | 100.7 ± 13.68 | 104.7 ± 14.98 | 94.32 ± 8.156 | 0.004 |
| Insulin, μIU/ml | 6.486 ± 3.833 | 7.178 ± 4.225 | 5.274 ± 2.718 | 0.076 |
| HOMA-IR | 1.591 ± 1.090 | 1.886 ± 1.183 | 1.122 ± 0.726 | 0.004 |
| Homocysteine, μmol/L | 10.44 ± 3.393 | 11.85 ± 3.343 | 8.195 ± 2.006 | <0.001 |
| HbA1c, % | 5.472 ± 0.366 | 5.543 ± 0.414 | 5.359 ± 0.240 | 0.064 |
| hs-CRP, mg/L | 0.686 ± 0.597 | 0.708 ± 0.667 | 0.652 ± 0.477 | 0.736 |
| Alcohol intake, wk | 66.67 ± 61.94 | 98.04 ± 54.88 | 16.77 ± 33.24 | <0.001 |
| Total energy intake, % | 98.63 ± 18.61 | 92.54 ± 14.10 | 108.3 ± 21.01 | 0.004 |
| Carbohydrate intake, % | 90.89 ± 34.92 | 88.51 ± 41.71 | 94.68 ± 20.25 | 0.521 |
| Protein intake, % | 109.2 ± 34.01 | 104.2 ± 32.28 | 117.0 ± 35.94 | 0.171 |
| Fat intake, % | 126.5 ± 45.45 | 113.0 ± 40.57 | 147.8 ± 45.44 | 0.004 |
| Metabolic syndrome, n (%) | 10 (17.54) | 8 (22.86) | 2 (9.091) | |
| Central obesity, n (%) | 14 (24.56) | 10 (28.57) | 4 (18.18) | |
| Hypertriglyceridemia, n (%) | 16 (28.07) | 12 (34.29) | 4 (18.18) | |
| Low HDL-C, n (%) | 12 (21.05) | 7 (20.00) | 5 (22.73) | |
| Impaired fasting glucose, n (%) | 10 (17.54) | 9 (25.71) | 1 (4.545) | |
| Hypertension, n (%) | 12 (21.05) | 9 (25.71) | 3 (13.64) | |
| Postmenopausal, n (%) | 10 (45.45) | – | 10 (45.45) |
Mean ± S.D. tested by independent t test, BMI body mass index, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein, cholesterol, AI (TC-HDL)/HDL, Apo B apolipoprotein B, FBS fasting blood sugar, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein; intake % percentage of recommended intake and the actual intake
Correlation analysis between erythrocyte membrane phospholipid fatty acids and cardiovascular risk factors
| BMI | Waist circumference | TG | Apo B | TC | LDL-C | HDL-C | SBP | DBP | FBS | Insulin | AI | HbA1c | HOMA-IR | homocysteine | hs-CRP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C14:0 Myristic acid | 0.283* | 0.285* | 0.480** | 0.130 | −0.053 | −0.100 | −0.322* | 0.150 | 0.177 | 0.308* | 0.429** | 0.343** | 0.173 | 0.457** | 0.145 | 0.088 |
| C16:0 Palmitic acid | 0.256 | 0.279* | 0.375** | −0.007 | −0.198 | −0.299* | −0.297* | 0.480** | 0.496** | 0.146 | 0.129 | 0.122 | 0.000 | 0.209 | 0.033 | 0.139 |
| C18:0 Stearic acid | 0.043 | 0.059 | −0.341** | −0.189 | −0.058 | 0.032 | 0.100 | −0.326* | −0.329* | −0.150 | −0.011 | −0.205 | −0.004 | −0.064 | −0.122 | −0.038 |
| C24:0 Lignoceric acid | −0.041 | 0.134 | −0.058 | −0.075 | −0.015 | 0.061 | 0.044 | −0.176 | −0.221 | 0.163 | −0.085 | −0.053 | 0.043 | −0.037 | 0.138 | −0.311* |
| C16:1n7, Palmitoleic acid | 0.059 | −0.022 | 0.454** | 0.114 | 0.091 | −0.079 | 0.023 | 0.140 | 0.209 | 0.228 | 0.098 | 0.078 | −0.008 | 0.123 | 0.088 | 0.122 |
| C18:1n9, Oleic acid | 0.099 | 0.213 | 0.523** | 0.345** | 0.021 | −0.068 | −0.157 | .0387** | 0.407** | 0.033 | 0.269* | 0.212 | 0.034 | 0.274* | 0.269* | 0.110 |
| C20:1n9, Eicosenoic acid | 0.093 | 0.043 | −0.328* | −0.107 | −0.156 | 0.022 | −0.127 | −0.288* | −0.249 | 0.072 | 0.054 | 0.012 | 0.171 | 0.076 | −0.184 | 0.115 |
| C24:1n9, Nervonic acid | −0.057 | 0.003 | −0.227 | −0.077 | 0.048 | 0.160 | 0.106 | −0.316* | −0.338* | 0.098 | −0.056 | −0.020 | 0.105 | −0.039 | 0.115 | −0.201 |
| C18:2n6 (LA) | −0.214 | −0.335* | −0.179 | 0.066 | 0.364** | 0.376** | 0.216 | −0.052 | −0.069 | −0.245 | −0.109 | 0.013 | −0.123 | −0.195 | −0.145 | 0.037 |
| C18:3n6 (GLA) | 0.125 | 0.090 | 0.359** | 0.085 | 0.049 | 0.033 | −0.219 | 0.018 | 0.044 | 0.324* | 0.349** | 0.265* | 0.250 | 0.286* | 0.029 | 0.041 |
| C20:2n6 (EDA) | −0.136 | −0.140 | −0.092 | 0.051 | 0.104 | 0.005 | 0.283* | −0.096 | −0.087 | −0.113 | −0.056 | −0.248 | 0.055 | −0.038 | 0.079 | −0.042 |
| C20:3n6 (DGLA) | 0.168 | 0.080 | 0.065 | 0.127 | 0.095 | 0.149 | −0.160 | 0.212 | 0.241 | 0.046 | 0.163 | 0.181 | 0.209 | 0.137 | 0.127 | 0.245 |
| C20:4n6 (AA) | −0.080 | −0.020 | −0.469** | −0.284* | −0.159 | 0.012 | 0.004 | −0.284* | −0.276* | −0.034 | −0.188 | −0.201 | 0.108 | −0.220 | −0.051 | 0.005 |
| C22:4n6 (DTA) | 0.165 | 0.147 | −0.244 | −0.147 | −0.084 | 0.065 | −0.140 | −0.027 | −0.011 | 0.145 | 0.165 | −0.037 | 0.131 | 0.130 | 0.003 | 0.064 |
| C22:5n6 (DPA) | −0.178 | −0.104 | 0.128 | 0.199 | 0.287* | 0.245 | 0.166 | −0.032 | −0.090 | −0.174 | −0.165 | −0.001 | −0.265* | −0.224 | 0.048 | −0.006 |
| C18:3n3 (ALNA) | 0.024 | −0.057 | 0.215 | 0.011 | −0.029 | −0.081 | −0.048 | 0.085 | 0.050 | 0.043 | 0.087 | 0.060 | −0.168 | −0.012 | −0.162 | 0.123 |
| C20:5n3 (EPA) | 0.181 | 0.202 | −0.166 | −0.113 | −0.221 | −0.237 | −0.041 | 0.017 | 0.032 | 0.138 | −0.035 | −0.053 | 0.063 | 0.055 | 0.063 | −0.150 |
| C22:5n3 (DPA) | 0.182 | 0.229 | −0.185 | −0.224 | −0.316* | −0.247 | −0.151 | −0.091 | −0.090 | 0.185 | −0.005 | −0.096 | 0.048 | 0.072 | −0.093 | −0.108 |
| C22:6n3 (DHA) | 0.874 | 0.075 | 0.039 | −0.117 | −0.143 | −0.227 | −0.107 | 0.044 | 0.036 | 0.114 | −0.147 | 0.008 | 0.011 | −0.082 | –.0810 | –.0582 |
| D5D | −0.233 | −0.126 | −0.035** | −0.291* | −0.179 | −0.117 | 0.158 | −0.366** | −0.400** | −0.056 | −0.248 | −0.302* | −0.155 | −0.240 | −0.179 | −0.228 |
| D6D | 0.191 | 0.191 | 0.365** | 0.048 | −0.070 | −0.078 | −0.284* | 0.003 | 0.049 | 0.383** | 0.364** | 0.089 | 0.303* | 0.330* | 0.087 | 0.044 |
| D9D | 0.042 | 0.119 | 0.546** | 0.318* | 0.016 | −0.097 | −0.167 | 0.453** | 0.459** | 0.060 | 0.179 | 0.226 | −0.020 | 0.196 | 0.236 | 0.127 |
Mean ± S.D.; Significantly correlated by pearson correlation analysis at *p <0.05, and **p <0.01 and respectively
AA Arachidonic acid, ALNA α-Linolenic acid, DGLA Dihomo-γ-linolenic acid, DHA Docosahexanoic acid, DPA Docosapentaenoic acid, DTA Docosatetraenoic acid, D5D delta-5-Desatuase (C20:4 ω-6/C20:3 ω-6), D6D delta-6-Desatuase(C18:3 ω-6/C18:2 ω-6), D9D delta-9-Desatuase(C18:1 ω-9/C18:0), EDA Eicosadienoic acid, EPA Eicosapentaenoic acid, GLA γ-linolenic acid, LA Linoleic acid, MUFA monosaturated fatty acid, PUFA polysaturated fatty acid, SFA saturated fatty acid, C22:5 ω-6(Docosapentaenoic acid, DPA) = osbond acid; C22:5 ω-3 (Docosapentaenoic acid, DPA) = clupanodonic acid, BMI body mass index, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, TG Triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein, cholesterol, AI (TC-HDL)/HDL, Apo B apolipoprotein B, FBS fasting blood sugar, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein
Fig. 1The pathway of the fatty acids and related fatty acid desaturases
Fig. 2Comparison of cardiovascular risk factor levels in quartile subgroups of fatty acid indices. (a) fasting blood glucose (FBS) levels in the quartile groups of delta 6 desaturase index (D6D), (b) fasting insulin levels in the quartile groups of D6D index, (c) triglyceride (TG) levels in the quartile groups of delta 9 desaturase (D9D) index and the sum of C14:0 and C16:0 (C14C16), (d) systolic blood pressure (SBP) levels in the quartile groups of D9D, delta 5 desaturase index (D5D) and C14C16, and (e) diastolic blood pressure (DBP) levels in the quartile groups of D9D, D5D and C14C16
Linear regression analysis with fatty acid indices and its associated risk factors
| R2 | adjR2 | B | S.E. | P | ||
|---|---|---|---|---|---|---|
| FBS | D6D | .150 | .135 | 31.28 | 10.04 | .003 |
| adj D6D | .278 | .223 | 25.59 | 9.702 | .011 | |
| Insulin | D6D | .082 | .065 | 6.403 | 2.942 | .034 |
| adj D6D | .172 | .105 | 5.062 | 2.946 | .092 | |
| TG | D9D | 0.454 | 0.433 | 439.5 | 101.09 | .000 |
| C14C16 | 23.76 | 5.561 | .000 | |||
| adj D9D | 0.518 | 0.471 | 496.7 | 102.4 | .000 | |
| adj C14C16 | 17.79 | 5.876 | .004 | |||
| SBP | D9D | 0.211 | 0.166 | 54.88 | 34.27 | .115 |
| D5D | −31.91 | 22.81 | .168 | |||
| C14C16 | 3.720 | 2.025 | .072 | |||
| adj D9D | 0.355 | 0.277 | 77.61 | 33.46 | .024 | |
| adj D5D | −27.29 | 21.30 | .206 | |||
| adj C14C16 | 1.560 | 2.025 | .445 | |||
| DBP | D9D | 0.235 | 0.192 | 39.68 | 23.25 | .094 |
| D5D | −22.56 | 15.47 | .151 | |||
| C14C16 | 2.785 | 1.374 | .048 | |||
| adj D9D | 0.329 | 0.248 | 51.95 | 23.52 | .032 | |
| adj D5D | −20.01 | 14.97 | .187 | |||
| adj C14C16 | 1.585 | 1.424 | .271 |
Tested by linear regression; adj adjusted after age, BMI body mass index and sex; FBS fasting blood sugar, TG Triglyceride, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, D5D delta-5-Desatuase (C20:4 ω-6/C20:3 ω-6), D6D delta-6-Desatuase (C18:3 ω-6/C18:2 ω-6), D9D delta-9-Desatuase (C18:1 ω-9/C18:0; C14C16 the sum of C14:0 (myristic acid) + C16:0 (palmitic acid)